JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

Benzinga Newsdesk www.benzinga.com Positive 76.1%

Neg 0% Neu 0% Pos 76.1%

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $76 to $83.